{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:34:11Z","timestamp":1780587251560,"version":"3.54.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Lenvatinib is a first-line agent for advanced hepatocellular carcinoma (HCC), but individual responses to treatment are highly heterogeneous. The aim of this study was to investigate the clinical parameters that influence the efficacy of Lenvatinib and to develop a prognostic model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively enrolled 333 Lenvatinib-treated patients with HCC with a median age of 57 years. Two hundred nd sixty-three of these patients had BCLC (2022) stage C. The median overall survival (mOS) time within the cohort was 12.1 months, and the median progression-free survival (mPFS) time was 4.7 months. Univariate Cox regression, best subset regression, and Lasso regression were used to screen primary variables for possible contribution to OS, multivariate Cox analysis was used to fit selected models, and the final model was selected using the maximum area under the curve (AUC) and minimum AIC. Receiver operating curves (ROC), calibration curves, and decision curve analysis were plotted to assess model performance, and 5-fold cross-validation was performed for internal validation. X-tile software was used to select the best cutoff points and to divide the study cohort into 3 different risk groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven variables were included in the final model: BCLC stage, prior transarterial chemoembolization and immunotherapy history, tumor number, prognostic nutritional index, log (alpha-fetoprotein), and log (platelet-to-lymphocyte ratio). We named this final model the \u201cmultivariate prognostic model for Lenvatinib\u201d (MPML), and a nomogram was constructed to predict the probability of survival at 6, 9, and 12 months. The MPML had good discrimination, calibration, and applicability. Cross-validation showed mean AUC values of 0.7779, 0.7738, and 0.7871 at 6, 9, and 12 months, respectively. According to nomogram points, mOS time was 21.57, 8.70, and 5.37 months in the low, medium, and high-risk groups, respectively (P &amp;lt; .001), and these differences were also observed in the PFS survival curve (P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The MPML stratified patients according to baseline clinical characteristics had a strong performance in predicting Lenvatinib efficacy and has the potential for use as an auxiliary clinical tool for individualized decision-making.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad107","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T22:14:14Z","timestamp":1682633654000},"page":"e942-e949","source":"Crossref","is-referenced-by-count":8,"title":["Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-6640","authenticated-orcid":false,"given":"Xiaomi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing You\u2019an Hospital, Capital Medical University , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1640-7115","authenticated-orcid":false,"given":"Jinglong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"issue":"3","key":"2023100311175841900_CIT0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2023100311175841900_CIT0002","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2023100311175841900_CIT0003","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"2023100311175841900_CIT0004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2023100311175841900_CIT0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, \u00adplacebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10126","key":"2023100311175841900_CIT0006","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"2023100311175841900_CIT0007","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"2023100311175841900_CIT0008","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023100311175841900_CIT0009","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12094-017-1720-4","article-title":"An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"20","author":"Diaz-Beveridge","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2023100311175841900_CIT0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2407-13-52","article-title":"The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma","volume":"13","author":"Kinoshita","year":"2013","journal-title":"BMC Cancer"},{"issue":"5","key":"2023100311175841900_CIT0011","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12072-020-10076-4","article-title":"Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib","volume":"14","author":"Ha","year":"2020","journal-title":"Hepatol Int"},{"issue":"56","key":"2023100311175841900_CIT0012","doi-asserted-by":"crossref","first-page":"95853","DOI":"10.18632\/oncotarget.21401","article-title":"The prognostic value of \u00adinflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib","volume":"8","author":"Conroy","year":"2017","journal-title":"Oncotarget"},{"key":"2023100311175841900_CIT0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2017.08.036","article-title":"Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a new application for the hepatoma arterial embolisation prognostic score","volume":"86","author":"Edeline","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023100311175841900_CIT0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41416-019-0488-4","article-title":"Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment","volume":"121","author":"Berhane","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"2023100311175841900_CIT0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/liv.14270","article-title":"Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib","volume":"40","author":"Labeur","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"2023100311175841900_CIT0016","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4143\/crt.2017.126","article-title":"Sub-classification of advanced-stage hepatocellular carcinoma: a Cohort study including 612 patients treated with sorafenib","volume":"50","author":"Yoo","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"5","key":"2023100311175841900_CIT0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000492628","article-title":"Improved prediction of survival by a risk factor-integrating inflammatory score in sorafenib-treated hepatocellular carcinoma","volume":"8","author":"Sprinzl","year":"2019","journal-title":"Liver Cancer"},{"issue":"4","key":"2023100311175841900_CIT0018","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/nu12041076","article-title":"Controlling Nutritional Status (CONUT) Score is associated with overall survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter cohort study","volume":"12","author":"Shimose","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"2023100311175841900_CIT0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000506293","article-title":"Nutritional Index as Prognostic Indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma","volume":"98","author":"Hiraoka","year":"2020","journal-title":"Oncology (Huntingt)"},{"issue":"7","key":"2023100311175841900_CIT0020","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/jgh.15336","article-title":"Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: analysis adjusted with inverse probability weighting","volume":"36","author":"Hiraoka","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2023100311175841900_CIT0021","doi-asserted-by":"crossref","first-page":"100190","DOI":"10.1016\/j.esmoop.2021.100190","article-title":"Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma","volume":"6","author":"Rapposelli","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"2023100311175841900_CIT0022","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"2023100311175841900_CIT0023","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"2023100311175841900_CIT0024","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1245\/s10434-015-4786-7","article-title":"Infiltrative hepatocellular carcinoma: natural history and comparison with multifocal, nodular hepatocellular carcinoma","volume":"22","author":"Yopp","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2023100311175841900_CIT0025","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1478-3231.2008.01957.x","article-title":"Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies","volume":"29","author":"Tandon","year":"2009","journal-title":"Liver Int"},{"issue":"4","key":"2023100311175841900_CIT0026","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00330-002-1519-7","article-title":"Extrahepatic spread of hepatocellular carcinoma: a pictorial review","volume":"13","author":"Hong","year":"2003","journal-title":"Eur Radiol"},{"issue":"10","key":"2023100311175841900_CIT0027","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jvir.2008.06.017","article-title":"Comparison of \u00adhypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors","volume":"19","author":"Virmani","year":"2008","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2023100311175841900_CIT0028","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3892\/ol.2020.11758","article-title":"Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: a multicenter cohort study using data mining analysis","volume":"20","author":"Shimose","year":"2020","journal-title":"Oncol Lett"},{"issue":"20","key":"2023100311175841900_CIT0029","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/cncr.33677","article-title":"Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study","volume":"127","author":"Ding","year":"15 2021","journal-title":"Cancer"},{"issue":"12","key":"2023100311175841900_CIT0030","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.3390\/jcm9124121","article-title":"A real-world comparative analysis of lenvatinib and sorafenib as a salvage therapy for transarterial treatments in unresectable HCC","volume":"9","author":"Lee","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"2023100311175841900_CIT0031","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023100311175841900_CIT0032","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"20 2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023100311175841900_CIT0033","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt.15.126","article-title":"Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Hato","year":"2016","journal-title":"Immunotherapy"},{"issue":"4","key":"2023100311175841900_CIT0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MEG.0000000000000558","article-title":"Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study","volume":"28","author":"Adhoute","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2023100311175841900_CIT0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/liv.13218","article-title":"Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma","volume":"37","author":"Chan","year":"2017","journal-title":"Liver Int"},{"issue":"9","key":"2023100311175841900_CIT0036","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"10","key":"2023100311175841900_CIT0037","doi-asserted-by":"crossref","first-page":"e0202987e0202987","DOI":"10.1371\/journal.pone.0202987","article-title":"The prognostic value of prognostic \u00adnutritional index in hepatocellular carcinoma patients: a \u00admeta-analysis of observational studies","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"2023100311175841900_CIT0038","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.3390\/cancers13112608","article-title":"The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a Nationwide Multicenter Study","volume":"13","author":"Tsuchiya","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2023100311175841900_CIT0039","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1159\/000485396","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review","volume":"44","author":"Zheng","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"2023100311175841900_CIT0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MEG.0000000000001734","article-title":"Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis","volume":"32","author":"Tada","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"2023100311175841900_CIT0041","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00535-022-01883-7","article-title":"Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade)","volume":"57","author":"Kariyama","year":"2022","journal-title":"J Gastroenterol"},{"key":"2023100311175841900_CIT0042","doi-asserted-by":"crossref","first-page":"6058147","DOI":"10.1155\/2016\/6058147","article-title":"Tumor-associated macrophages and neutrophils in tumor microenvironment","volume":"2016","author":"Kim","year":"2016","journal-title":"Mediators Inflamm"},{"issue":"6835","key":"2023100311175841900_CIT0043","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/35077246","article-title":"Progress in human tumour immunology and immunotherapy","volume":"411","author":"Rosenberg","year":"2001","journal-title":"Nature"},{"issue":"30","key":"2023100311175841900_CIT0044","first-page":"E3053","article-title":"Platelets guide the formation of early metastatic niches","volume":"111","author":"Labelle","year":"2014","journal-title":"Proc Natl Acad Sci \u00adUSA"},{"issue":"5","key":"2023100311175841900_CIT0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e942\/51821295\/oyad107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e942\/51821295\/oyad107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:24:38Z","timestamp":1696332278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/10\/e942\/7146138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,4,27]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad107","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,4,27]]}}}